CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Portland, Oregon, United States and 35 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Portland, Oregon, United States and 40 other locations
is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...
Phase 1
Portland, Oregon, United States and 9 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Portland, Oregon, United States and 46 other locations
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Ani...
Phase 2
Portland, Oregon, United States and 19 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Portland, Oregon, United States and 25 other locations
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...
Phase 3
Salem, Oregon, United States and 140 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Portland, Oregon, United States and 278 other locations
the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple...
Phase 1, Phase 2
Portland, Oregon, United States and 39 other locations
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of ...
Phase 1
Portland, Oregon, United States and 12 other locations
Clinical trials
Research sites
Resources
Legal